PLCG2外显子跳跃变异在慢性淋巴细胞白血病中的潜在作用
研究在长期替拉鲁替尼处理的REC-1细胞中发现PLCG2剪接位点突变c.2236-1G>T,并在伊布替尼进展患者中检出同一剪接位点缺失,均导致外显子跳跃变异Δ21且磷脂酶活性增强。Δ21细胞抗IgM介导钙流增加、对BTK抑制耐药但保留对PLCγ抑制剂敏感;原代CLL中还广泛表达Δ22和Δ20-22,Δ20-22在维奈克拉治疗后表达下降(P = .02),伊布替尼治疗后无变化。
要点
- PLCG2剪接位点改变导致Δ21外显子跳跃变异,增强磷脂酶活性并介导BTKi耐药。
- Δ21细胞对BTK抑制耐药但保留对PLCγ抑制剂敏感,提示潜在治疗选择。
- Δ20-22在CLL中高表达,维奈克拉治疗后下降而伊布替尼治疗后持续存在。
核心结论
- PLCG2剪接位点改变及外显子跳跃变异(Δ21、Δ22、Δ20-22)可能参与BTKi耐药,并可为治疗选择提供信息。
研究设计与样本
- 以长期替拉鲁替尼处理获得耐药的REC-1细胞为模型,并结合伊布替尼进展患者及额外原代CLL样本进行分析。
主要发现
- REC-1细胞获得PLCG2剪接位点突变c.2236-1G>T,伊布替尼进展患者CLL中检出同一剪接位点缺失c.2236-23_2238。
- 上述改变导致外显子跳跃变异Δ21,其磷脂酶活性增强。
- PLCG2剪接位点突变REC-1细胞抗IgM介导钙流增加、对BTK抑制耐药,但保留对PLCγ抑制剂敏感。
- 原代CLL中广泛表达Δ22和Δ20-22,且不依赖PLCG2基因改变;活性Δ20-22在CLL中较健康供者样本更常见。
- 维奈克拉治疗后Δ20-22表达下降(P = .02),伊布替尼治疗后无变化。
临床怎么用
- 对BTKi耐药或疾病进展的CLL患者,可考虑评估PLCG2剪接位点改变及外显子跳跃变异。
- 携带Δ21等外显子跳跃变异的CLL可能对PLCγ抑制剂敏感,可作为后续治疗选择参考。
- 伊布替尼治疗下Δ20-22可能持续存在,维奈克拉治疗后其表达可下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bruton tyrosine kinase inhibitors (BTKi) are successful in the treatment of chronic lymphocytic leukemia (CLL), yet acquired resistance remains a challenge. In our study, REC-1 cells that acquired resistance to the BTKi tirabrutinib by long-term treatment gained a splice site mutation (SSM) c.2236-1G>T in phospholipase C gamma 2 (PLCG2). Notably, a deletion spanning c.2236-23_2238 at the same splice site was identified in CLL from a patient who had disease progression during ibrutinib therapy. These alterations resulted in the exon-skipped variant Δ21, which exhibited enhanced phospholipase activity. PLCG2 SSM REC-1 exhibited increased anti-immunoglobulin M-mediated calcium flux and resistance to BTK inhibition but retained sensitivity to PLCγ inhibitors. By analyzing additional primary CLL samples, we identified widespread expression of 2 additional exon-skipped variants, Δ22 and Δ20-22, independent of PLCG2 genetic alterations. The active Δ20-22, which is also described in PLCG2-associated immune dysregulation, was predominantly present in CLL compared to healthy donor samples. Expression analysis in CLL cells isolated from patients before and after targeted treatments revealed a decrease in the expression of Δ20-22 after venetoclax treatment (P = .02), whereas no change in expression was observed after ibrutinib treatment, indicating that these variants may persist in the presence of ibrutinib but might be lost in the absence of drug selection pressure. Our study reveals novel PLCG2 splice site alterations and exon-skipped variants beyond the classical BTK or PLCG2 mutations to have a potential role in BTKi resistance and inform treatment selection.
引用
- Qi J, Li W, Dheenadayalan RP, et al. PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. Blood Adv. 2026. PMID: 42263669. doi:10.1182/bloodadvances.2025019077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。